Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’) read with part A of Schedule III of the Listing Regulations, Gujarat Themis Biosyn has informed that the management of the Company will have a meeting with Analysts/Investors on Thursday, 1st December 2022; the details of the same are enclosed. The schedule of the aforesaid meetings is subject to change and changes may happen due to exigencies on the part of Fund / Broking House / Company. No Unpublished Price Sensitive Information (UPSI) will be discussed in the meetings/calls. Pursuant to regulation 46(2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the company: www.gtbl.in.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: